New drug shows promise against pancreatic cancer

nature.com

An experimental drug, daraxonrasib, has nearly doubled survival for advanced pancreatic cancer patients. The drug targets all three RAS proteins, notoriously difficult to drug, disarming them and halting tumor growth. This marks a significant advance after over a decade without major treatment progress. This success offers hope for developing treatments against other "undruggable" cancer targets like MYC and p53, which also present significant challenges for drug development.


With a significance score of 6.8, this news ranks in the top 0.1% of today's 33817 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers: